Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes

Table 3 Factors associated with the severity of HFS and fatigue

	HFS p = 0.02			Fatigue F(13,82) = 2.51, p = 0.006, R-squared = 0.28
	β	SE	p	β	SE	p
Age \(\ge 65\)	1.15	0.40	.004	0.44	0.20	.03
Female	-0.07	0.43	.85	-0.45	0.22	.05
White	0.10	0.52	.83	-0.01	0.29	.97
Other cancer	Ref			Ref
Breast Cancer	0.79	0.76	.30	0.11	0.39	.76
Pancreatic Cancer	0.57	0.56	.31	0.22	0.24	.36
Colorectal Cancer	1.10	0.60	.06	0.36	0.32	.26
Advanced/metastatic stage	0.11	0.40	.77	-0.34	0.20	.10
Initial daily dose (g)	0.30	0.21	.14	0.03	0.11	.78
Days on treatment	0.50	0.19	.009	0.08	0.09	.35
Combination treatment	-0.14	0.42	.73	-0.005	0.23	.98
14 days on, 7 days off cycle	-0.35	0.39	.35	-0.04	0.20	.82
Number of outpatient medications	-0.009	0.04	.81	0.06	0.02	0.006
Number of comorbidities	-3.90	0.09	0.42	0.008	0.04	.84

ISSN: 1471-2407